Search

Your search keyword '"Wu, Song-Yang"' showing total 10 results
Start Over Author "Wu, Song-Yang" Publisher american association for cancer research (aacr)
10 results on '"Wu, Song-Yang"'

1. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

8. Abstract OT3-27-01: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial

Author

Shao, Zhi-Ming, primary, Wang, Zhong-Hua, additional, Jiang, Yi-Zhou, additional, Liu, Yin, additional, Zhu, Xiu-Zhi, additional, Xiao, Yi, additional, Wu, Song-Yang, additional, Zuo, Wen-Jia, additional, Yu, Qiang, additional, Cao, A-Yong, additional, Li, Jun-Jie, additional, Yu, Ke-Da, additional, Liu, Guang-Yu, additional, Wu, Jiong, additional, Sun, Tao, additional, Cui, Jiuwei, additional, Lv, Zheng, additional, Li, Hui-Ping, additional, and Zhu, Xiao-Yu, additional

Published
2023
Full Text
View/download PDF

10. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, additional, Wu, Song-Yang, additional, Wu, Jiong, additional, Di, Gen-Hong, additional, Liu, Guang-Yu, additional, Yu, Ke-Da, additional, Fan, Lei, additional, Li, Jun-Jie, additional, Hou, Yi-Feng, additional, Hu, Zhen, additional, Chen, Can-Ming, additional, Huang, Xiao-Yan, additional, Cao, A-Yong, additional, Hu, Xin, additional, Zhao, Shen, additional, Ma, Xiao-Yan, additional, Xu, Ying, additional, Sun, Xiang-Jie, additional, Chai, Wen-Jun, additional, Guo, Xiaomao, additional, Chen, Xizi, additional, Xu, Yanhui, additional, Zhu, Xiao-Yu, additional, Zou, Jian-Jun, additional, Yang, Wen-Tao, additional, Wang, Zhong-Hua, additional, and Shao, Zhi-Ming, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results